Abstract: Objective To study the efficacy of ribavirin combined with sofbuvir and dalatavir in the treatment of genotype 1b low viral load chronic hepatitis C. Methods From August 2018 to August 2020, 90 patients with chronic HCV infection due to low viral load of genotype 1b in our hospital were randomly divided into group A and group B, with 45 cases in each group, Group A was treated with conventional ribavirin combined with subcutaneous injection of ethylene glycol interferon α, and group B was treated with sothibuvir combined with dalatavir on the basis of conventional ribavirin combined with subcutaneous injection of ethylene glycol interferon α, The levels of alanine aminotransferase (ALT), total bilirubin (TBIL) and aspartate aminotransferase (AST) before and after treatment were compared between the two groups, and the incidence of adverse reactions during treatment was compared between the two groups. Results There was no significant difference in the negative rate of HCV-RNA (62.22%vs66.67%,86.67%vs91.11%,93.33%vs93.33%)and the incidence of SVR(91.11%vs93.33%,84.44%vs88.89%,80.00%vs86.67%) between the two groups at each time point (P>0.05); the negative rate of HCV-RNA(86.67%、93.33%vs62.22,91.11%、93.33%vs66.67%) in the two groups at 8 weeks and 12 weeks of treatment was significantly higher than that at 4 weeks of treatment, and the difference was statistically significant (P<0.05).After treatment, AST [(27.56±4.32)U/L]and ALT[(35.42±6.71)U/L] in group B were significantly lower than those before treatment[(72.58±6.43)U/L、(117.58±15.46)U/L] and the group A[(31.25±5.34)U/L、(42.38±5.47)U/L], the difference was statistically significant (P<0.05); TBil in two groups after treatment[(18.54±2.34)、(18.16±2.54)μmol/L] was significantly lower than that before treatment[(20.46±4.31)、(20.53±4.38)μmol/L], the difference was statistically significant (P<0.05).The total incidence of adverse reactions in group A was 31.11%, which was not significantly different from 46.67% in group B (P>0.05). Conclusion Ribavirin combined with sofbuvir and dalatavir has good clinical efficacy in the treatment of genotype 1b low viral load chronic hepatitis C.
   

Key words: Genotype 1b hepatitis C, Low load virus, Ribavirin, Sofbuvir, Dalatavir